Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that HER2-negative, PD-L1 (TAP) >= 1% status confers therapeutic sensitivity to Cisplatin, Fluorouracil, Tislelizumab in patients with Adenocarcinoma of the Gastroesophageal Junction.
This statement is based on a regulatory approval from the Food and Drug Administration:
TEVIMBRA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with platinum and fluoropyrimidine-based chemotherapy in adults for the first line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocracinoma whose tumors express PD-L1 (>=1).